File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study

TitleAnti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study
Authors
Issue Date2012
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR
Citation
Clinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210 How to Cite?
Abstract
AIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.
DescriptionOn behalf of the Implant Complication Research Group
Persistent Identifierhttp://hdl.handle.net/10722/145507
ISSN
2013 Impact Factor: 3.123
ISI Accession Number ID
Funding AgencyGrant Number
ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI)341/04
Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF)16/05
Funding Information:

This multicentre study was supported by a grant of the ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI grant Nr. 341/04) and the Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF grant Nr. 16/05.

 

Author Affiliations
  1. The University of Hong Kong
  2. University of Western Australia
  3. Université de Genève
  4. Universität Bern
  5. Queensland University of Technology
DC FieldValueLanguage
dc.contributor.authorHeitz-Mayfield, LJAen_US
dc.contributor.authorSalvi, GEen_US
dc.contributor.authorMombelli, Aen_US
dc.contributor.authorFaddy, Men_US
dc.contributor.authorLang, NPen_US
dc.date.accessioned2012-02-28T01:52:59Z-
dc.date.available2012-02-28T01:52:59Z-
dc.date.issued2012en_US
dc.identifier.citationClinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210en_US
dc.identifier.issn0905-7161en_US
dc.identifier.urihttp://hdl.handle.net/10722/145507-
dc.descriptionOn behalf of the Implant Complication Research Group-
dc.description.abstractAIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR-
dc.relation.ispartofClinical Oral Implants Researchen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subject.meshAmoxicillin - therapeutic use-
dc.subject.meshAnti-Bacterial Agents - therapeutic use-
dc.subject.meshDebridement - methods-
dc.subject.meshDecontamination - methods-
dc.subject.meshPeri-Implantitis - surgery-
dc.titleAnti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical studyen_US
dc.typeArticleen_US
dc.identifier.emailHeitz-Mayfield, LJA: heitz.mayfield@iinet.net.auen_US
dc.identifier.emailLang, NP: nplang@hkucc.hku.hk-
dc.identifier.authorityLang, NP=rp00031en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1600-0501.2011.02276.x-
dc.identifier.pmid22092831-
dc.identifier.scopuseid_2-s2.0-84855919545-
dc.identifier.hkuros198615en_US
dc.identifier.volume23en_US
dc.identifier.issue2en_US
dc.identifier.spage205en_US
dc.identifier.epage210en_US
dc.identifier.isiWOS:000299098700010-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats